Cyted Health Expands US Presence with First Patients Enrolled in DETECT-ME Clinical Validation Study
WILMINGTON, Del. and CAMBRIDGE, England, March 25, 2025 /PRNewswire/ — Cyted Health, a leading gastrointestinal molecular diagnostics company, today announces the enrollment of the first patient in the DETECT-ME clinical validation study (NCT06803927). The study evaluates Cyted Health’s advanced molecular assays using esophageal cells collected with the FDA 510(k)-cleared EndoSign® cell collection device to detect Barrett’s Esophagus (BE) and esophageal adenocarcinoma (EAC). The DETECT-ME study, co-led by principial investigators Dr. Nick Shaheen (Professor of Medicine & Senior Associate Dean for Clinical Research at the University of North Carolina School of Medicine) and Dr. Sachin Wani (Professor of Medicine, Gastroenterology, University of Colorado Anschutz Medical Center, Executive Director, Rady Esophageal & Gastric Center of Excellence), will enroll individuals across 18 sites in the US. This study builds upon Cyted Health’s extensive portfolio of peer-reviewed research and real-world clinical experience in the UK, where its technology has been widely adopted.
